Hep C showdowns; M&A mania;

Get out your binoculars for FiercePharma's traditional holiday trend-spotting

> Slimdown craze still on, with sales and spinoffs galore. Slim fast? Not necessarily. More

> Will biopharma keep riding that mammoth M&A wave? Short answer's yes. More

> Limited attention span? Focus on these market shake-ups in 2015. More

> Get ready to negotiate, drugmakers: Payers are armed for drug-pricing battle. More

> Continuous manufacturing reaches a turning point. More

Subscribe to FiercePharma >>

The 5 top trends for med tech in 2014

> Merger mania remakes the landscape. More

> Med tech tackles tough problems. More

> The rapid consumerization of med tech. More

> Google goes after med tech, along with other VCs. More

> Reimbursement continues to be a challenge. More

Subscribe to FierceMedicalDevices >>

Free Webinar

From Patient Adherence to Manufacturing Ease - Why Softgels Make Sense for Rx

Join Thermo Fisher Scientific’s upcoming webinar to learn why softgels offer numerous benefits for Rx drug development, including enhanced bioavailability, patient compliance and easy scale-up. Register Today.

Suggested Articles

Polyphor is developing an inhaled version of murepavadin, which targets Pseudomonas aeruginosa infections, but is currently given intravenously.

Japanese pharma Astellas is looking to offload a series of unwanted research projects ahead of Thanksgiving; if you want one, it’s made it very easy.

A re-engineered adenovirus prolonged survival in mouse models of metastatic lung cancer and cleared tumors in about 35% of the animals.